Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.41 |
| ▸ | CA2 | P00918 | 8/20 | 0.41 |
| ▸ | CA9 | Q16790 | 8/20 | 0.41 |
| ▸ | CA1 | P00915 | 7/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.36 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28658656 | 0.98 | CA12 (0.40) | CA12CA2CA9CA1CA14 | |
| SCHEMBL13089921 | 0.83 | GAA (0.45) | CA12CA2CA9CA1CA14 | |
| SCHEMBL2879049 | 0.81 | NAPRT (0.44) | CA12CA2CA9CA1CA14 | |
| SCHEMBL51312 | 0.81 | CA12 (0.58) | CA12CA2CA9CA1CA14 | |
| SCHEMBL5700130 | 0.81 | CYP17A1 (0.42) | CA12CA2CA9CA1CA14 | |
| Hydrochloric Acid SCHEMBL5689104 | 0.79 | CA12 (0.56) | CA12CA2CA9CA1CA14 | |
| Hydrochloric Acid SCHEMBL7862325 | 0.79 | NAPRT (0.42) | CA12CA2CA9CA1CA14 | |
| SCHEMBL27327312 | 0.78 | CYP17A1 (0.40) | CA12CA2CA9CA1CA14 | |
| SCHEMBL30727320 | 0.78 | CYP17A1 (0.40) | CA12CA2CA9CA1CA14 | |
| SCHEMBL7874188 | 0.77 | CA12 (0.44) | CA12CA2CA9CA1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232106-A | Preparation method of vorexan fumarate impurity | 南京唯创远医药科技有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-114441655-A | Torasemide genotoxicity impurity detection method | 康普药业股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-113620868-A | Torasemide new impurity and preparation method thereof | 南京恒正药物研究院有限公司 | 2021-11-09 | — | — | CN | claimed |
| WO-2003097603-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE TORSEMIDE | FINETECH LABORATORIES LTD. (IL) | 2003-11-27 | — | — | WO | claimed |
| WO-1997046553-A1 | THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | claimed |
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| US-12404248-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250084077-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| EP-4201924-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-3891137-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240309005-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 | THRYV THERAPEUTICS INC. (CA) | 2024-09-19 | — | — | US | disclosed |
| US-12091409-B2 | Ether linked triazoles as NRF2 activators | ASTEX THERAPEUTICS LIMITED (GB) | 2024-09-17 | — | — | US | disclosed |
| US-6258817-B1 | PRODRUGS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | ZENECA LTD. (GB) | 2001-07-10 | — | — | US | disclosed |
| EP-1048654-A2 | Process for the preparation of chloropyridine sulfonyl chloride | Rütgers Organics GmbH (DE) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000063177-A1 | METHOD OF PRODUCING CHLOROPYRIDINE SULFONIC ACID CHLORIDES | RÜTGERS ORGANICS GMBH (DE) | 2000-10-26 | — | — | WO | disclosed |
| US-5869428-A | CONTROLLING WEEDS | ISHIHARA SANGYO KAISHA LTD. (JP) | 1999-02-09 | — | — | US | disclosed |
| CN-1192739-A | N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists | ZENECA LTD (GB) | 1998-09-09 | — | — | CN | disclosed |
| WO-1997046553-A1 | THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
| EP-0733629-A1 | Pyridonesulfonylurea compounds, process for their production and herbicides containing them | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1996-09-25 | — | — | EP | disclosed |
| US-5459138-A | Dysfunctions of glutamatergic neurotransmission associated with learning and memory | ADIR ET COMPAGNIE (FR) | 1995-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084077-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | CA12 4874/4885CA2 4168/4885CA9 4689/4885 |
| US-20240309005-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 | PGK1, SGK1, PGK2 | CA12 4882/4885CA2 4421/4885CA9 4656/4885 |
| US-12091409-B2 | Ether linked triazoles as NRF2 activators | NFE2L2, KEAP1, NQO1 | CA12 4874/4885CA2 4168/4885CA9 4689/4885 |
| US-12552757-B2 | NRF2-activating compound | NFE2L2, NFE2, KEAP1 | CA12 4789/4885CA2 2738/4885CA9 4490/4885 |
| US-12404248-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CA12 4598/4885CA2 4217/4885CA9 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.